The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Mckesson Corp's Score
Industry at a Glance
Industry Ranking
5 / 160
Overall Ranking
26 / 4623
Industry
Pharmaceuticals
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
18
analysts
Buy
Current Rating
837.446
Target Price
+4.08%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Mckesson Corp Highlights
StrengthsRisks
McKesson Corporation is a provider of diversified healthcare services. It is engaged in advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over the counter (OTC) pharmaceutical drugs and other healthcare-related products in the United States. Its Prescription Technology Solutions segment helps solve medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Its Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home healthcare agencies. Its International segment includes its operations in Norway, which provides distribution and services to wholesale and retail customers.
Industry Leader
The company's revenue leads the industry, with the latest annual revenue totaling USD 359.05B.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 29.76% year-on-year.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 10.68%.
Overvalued
The company’s latest PE is 32.19, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 112.13M shares, decreasing 2.77% quarter-over-quarter.
McKesson Corporation is a provider of diversified healthcare services. It is engaged in advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over the counter (OTC) pharmaceutical drugs and other healthcare-related products in the United States. Its Prescription Technology Solutions segment helps solve medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Its Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home healthcare agencies. Its International segment includes its operations in Norway, which provides distribution and services to wholesale and retail customers.